

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

RESUMPTION OF TRADING

Reference is made to the trading halt announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) dated 23 May 2024.

The Company notes that trading in the H shares of its subsidiary Shanghai Henlius Biotech, Inc. (“**Henlius**”) has been halted as stated in Henlius’ trading halt announcement dated 23 May 2024. The Company has indicated to Henlius that there is a possible transaction pursuant to the Code on Takeovers and Mergers involving Henlius being contemplated.

Trading in the H shares of the Company has been halted with effect from 9:00 a.m. on 23 May 2024 pending the publication of this announcement. Given this announcement on the above, the Company has applied for the resumption of trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited with effect from 9:00 a.m. on 24 May 2024.

Shareholders and potential investors of the Company should be aware that there is no assurance that the transaction involving Henlius will proceed. Shareholders and potential investors of the Company are advised to exercise caution in dealing in the securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

23 May 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* For identification purposes only